Jazz Pharmaceuticals (JAZZ) has released an update.
Jazz Pharmaceuticals plc has appointed Philip Johnson as its new Executive Vice President and Chief Financial Officer, set to take the reins on March 1, 2024. With a solid background from Eli Lilly and Company, Inc., and a strong academic foundation in finance, Johnson steps in with a handsome compensation package, including a $700,000 base salary, a potential 65% bonus, a $150,000 signing bonus, and a substantial $4 million new hire equity grant. His financial acumen will now steer Jazz Pharmaceuticals’ fiscal strategies and contribute to its growth in the biotech sector.
For further insights into JAZZ stock, check out TipRanks’ Stock Analysis page.
